As most hepatocellular carcinoma (HCC) patients have cirrhosis, the association between diabetes and HCC may be confounded by the fact that diabetes is common in patients with cirrhosis. The aim of this study is to investigate whether diabetes increases the risk of HCC in patients with cirrhosis and whether the etiology of liver disease modifi es the association between diabetes and HCC.
INTRODUCTION
Th e incidence of hepatocellular carcinoma (HCC) in the US has tripled over the past three decades, from 1.5 to 4.9 cases per 100,000 per year ( 1 ) . Th e main driver of this rise in HCC incidence is commonly attributed to increasing disease burden of hepatitis C virus (HCV) infection ( 2 ) . Recently, non-alcoholic fatty liver disease (NAFLD) has been reported to be the third leading cause of HCC in the population-based/referral center based cohort studies ( 3, 4 ) . Of known risk factors for HCC, diabetes is reported to have the greatest population-attributable fraction in the US ( 5 ) .
Most epidemiologic studies have reported a two-to three-fold increase in the risk of HCC in patients with diabetes, regardless of the study design (case-control studies, cohort studies and meta-analyses) ( 6, 7 ) . Some of the association may be attributable to HCC occurring in patients with NAFLD many of whom have diabetes. Moreover, even in patients with cirrhosis from etiology other than NAFLD, progression of liver dysfunction is accompanied by insulin resistance and higher prevalence of diabetes ( 8, 9 ) . In contrast, there are studies, oft en from hepatitis B virus (HBV) endemic areas, in which no association between diabetes and HCC is found (10) (11) (12) . Th e association between diabetes and HCC could be further obscured given that HCV infection increases the risk of diabetes ( 13 ) . Th ese confl icting data may be in part due to the complex relationship between diabetes and cirrhosis from diff erent etiologies. It is clear that in studying the causal eff ect of diabetes on the risk of HCC, the etiology and severity of the underlying liver disease must be taken into account. Th us, in this work, we investigate (1) the degree to which diabetes is an independent risk factor for HCC in patients with cirrhosis and (2) the potential interaction between liver disease etiology and diabetes as a risk factor for HCC.
Diabetes Mellitus Heightens the Risk of Hepatocellular

METHODS
Patients
Th e primary analysis in this study was based on all patients with the diagnosis of cirrhosis of the liver seen at Mayo Clinic Rochester between January 2006 and December 2011. By querying an institutional database, we identifi ed all patients with cirrhosis, as defi ned by liver histology, features of portal hypertension (splenomegaly, esophageal varices, thrombocytopenia (platelet <150 K), ascites, or hepatic encephalopathy), or radiographical evidence in the setting of chronic liver disease. Our study population consisted of patients who underwent ultrasound, computed tomography, or magnetic resonance image more than once at least 6 months apart. Th us, patients who did not have more than 6 months of radiographical follow-up, including those who underwent liver transplantation (LT) or died within 6 months of initial assessment were excluded ( N =746). In addition, patients with previous history of HCC or HCC diagnosed at the initial evaluation or within 6 months thereaft er were excluded ( N =132). Finally, patients who initially presented with cholangiocarcinoma in the setting of liver cirrhosis ( N =3) were excluded. Th e study was approved by the institutional review board of Mayo Foundation.
We validated the results of our analysis using data from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial ( 14 ) . In brief, patients with chronic hepatitis C with compensated liver function, who failed to achieve sustained virologic response aft er previous interferon treatment and had histological evidence of advanced hepatic fi brosis or cirrhosis were enrolled in a randomized trial evaluating the potential benefi t of 3.5 years of peginterferon alfa-2a treatment in reducing the progression of liver disease or development of HCC ( ref. 15 ) . Among 428 patients with cirrhosis at baseline, 18 patients were excluded (17-<6 month follow-up; 1-HCC outcome was not able to be determined per HALT-C investigators) ( 15 ) . At the time of enrollment, patients were required to undergo ultrasound, computed tomography or magnetic resonance image to exclude possible HCC. During the follow-up, abdominal ultrasound was performed at the time of randomization, 6 months aft er randomization, and every 6-12 months thereaft er.
HCC ascertainment
HCC was defi ned by histologic confi rmation ( n =30) or clinical diagnostic criteria ( n =39) following the American Association For the Study of the Liver Disease (AASLD) guideline updated in 2011 ( refs 16-18 ) . Th e latter criteria included a new liver mass of at least 1 cm in diameter with characteristic features of HCC including both arterial enhancement and delayed washout on dynamic magnetic resonance image or four phasic computed tomography scan. In addition, we included patients who had lesions with compatible cross-sectional and angiographic imaging characteristics and underwent HCC-specifi c locoregional treatment such as transarterial chemoembolization or radioembolization ( n =10).
Ascertainment of HCC in the HALT-C study was published previously-either by histology or following clinical diagnosis criteria ( 15 ) . Th e latter criteria consisted of (1) a new mass lesion on imaging and (2) serum alpha fetoprotein levels increasing to ≥1,000 ng/ ml. Clinically suspicious lesions with the following criteria were characterized as presumed HCC: (1) two or more imaging studies showing a mass lesion in the liver with arterial enhancement with/ without washout, (2) progressively enlarging lesions on ultrasound leading to death of the patient, or (3) a mass lesion with arterial enhancement with/without washout that increased in size or was accompanied by rising serum levels of alpha fetoprotein. All cases of HCC were individually adjudicated by a panel of investigators.
Clinical information
In Mayo patients, clinical information at the time of initial evaluation was collected by medical record review. It included demographic data such as age, sex, and race and clinical characteristics including the etiology of underlying liver disease, severity of hepatic decompensation, as measured by the Child Turcotte Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores, and laboratory results. Diabetes was defi ned any of the following criteria: (i) documented history of diabetes, (ii) administration of a diabetes medication, or (iii) fasting glucose ≥126 mg/dl or HgbA1C ≥6.5 on two separate occasions. HCV infection was defi ned by detectable HCV RNA or positive Anti-HCV antibody with a documented history of chronic liver disease. HBV infection was diagnosed by positive serum hepatitis B virus surface antigen. Alcoholic liver disease was designated by history of alcohol abuse or dependence, or documented alcohol consumption of more than 20 gm daily for men and 10 gm daily for women. NAFLD consisted of radiographical diagnosis of steatosis in the absence of alcoholic liver disease, other chronic liver disease (viral, autoimmune or inherited metabolic, or biliary liver disease), or cryptogenic cirrhosis with metabolic syndrome ( 19 ) .
From the HALT-C data set, baseline demographics, severity of liver disease, diabetes, and laboratory data including HOMA2-IR at the time of enrollment were extracted. Diabetes was defi ned by self-reported medical history or fasting serum glucose concentrations ≥126 mg/dl on two separate occasions.
Statistical analysis
Clinical characteristics of the study population were compared using the Student t -test for continuous variables and the χ 2 test for categorical variables. Th e incidence of HCC was described by the Kaplan-Meier method and was compared by the log-rank test. Th e Cox proportional hazard regression analysis was used to investigate the eff ect of diabetes on the risk of HCC. Patients without HCC were censored at the time of the last radiographical assessment of the liver or at the time of LT or death. Patients were followed until 15th April 2015. JMP 10 (SAS Institute, Cary, NC, USA) was used for the statistical analysis.
LIVER Etiology Specific Effect of Diabetes on HCC Risk
RESULTS
Patient characteristics
Th e primary analysis of this study included 739 patients at Mayo Clinic, of whom 253 (34%) had diabetes ( Table 1 ) . Th e mean age was 57 years and 59% were male. Most patients (90%) were Caucasian. Alcohol (32%), NAFLD (23%), and HCV (21%) were the main etiology of cirrhosis. Other etiology (22%) included cirrhosis from autoimmune hepatitis ( n =34), primary biliary cirrhosis ( n =33), primary sclerosing cholangitis ( n =30), cryptogenic ( n =20), cardiac ( n =13), alpha 1-antitrypsin ( n =10), hemochromatosis ( n =8), sarcoidosis ( n =4), Wilson's disease ( n =2), drug ( n =2), and other rare causes ( n =4).
NAFLD was the leading cause of cirrhosis in patients with diabetes while alcohol was most common among patients without diabetes ( P <0.01). As expected, body mass index (BMI) was higher in patients with diabetes compared with patients without diabetes. Patients had mostly compensated or mildly decompensated liver disease: slightly more than half had no evidence of ascites and most patients did not have hepatic encephalopathy. Th e severity of hepatic decompensation, as measured by the mean CTP and MELD scores were lower in patients with diabetes compared with those without diabetes. In contrast, serum creatinine was higher in diabetic patients.
A total of 102 (40%) patients with diabetes and 139 (29%) without died during the follow-up. Patients with diabetes had a shorter survival ( Supplementary Figure S1 online) with a univariate hazard ratio (HR) of 1.5 (95% CI: 1.2-1.9, P <0.01). In contrast, 21 (8%) patients with diabetes and 62 (13%) without underwent LT. Th ere was a trend for patients with diabetes to be less likely to receive LT compared with those without diabetes ( Supplementary Figure S2 ) with a univariate HR of 0.7 (95% CI: 0.4-1.1, P =0.08).
Association between diabetes and risk of HCC
Aft er a median follow-up of 38 months, 69 (9%) patients developed HCC including 27 with diabetes and 42 without. Figure 1 displays the eff ect of diabetes on HCC incidence in the fi ve categories of liver disease. Although some of the categories only included small number of patients (e.g., HBV), patients with diabetes experienced a higher incidence of HCC except those with HCV. Univariate hazard ratios for diabetes were 0.8 (95% confi dence interval (CI)=0.4-1.8) for HCV, compared with 2.4 (95% CI=0.6-15.8) for NAFLD, 4.7 (95% CI=0.2-119.9) for HBV, 1.7 (95% CI=0.6-4.6) for alcoholic liver disease, and 4.5 (95% CI=0.6-23.1) for other etiology. When all of the non-HCV groups were combined together, the association between diabetes and HCC became clearer ( Figure 1f ) . Th e univariate hazard ratio for diabetes for non-HCV patients was 2.1 (95% CI=1.1-4.1, P =0.02). Table 2 summarizes a series of proportional hazard regression analyses, considering baseline variables shown in Table 1 as potential predictors of HCC. In univariate analyses, male gender, cirrhosis etiology, and low serum albumin level were signifi cant predictors of HCC development. With 'other' etiology as the reference group, HCV, HBV, alcoholic liver disease, and NAFLD were associated with higher hazards of HCC. However, no signifi cant association with HCC was found for age, BMI, CTP, or MELD. Although diabetes was associated with higher BMI, BMI was not associated with the risk of HCC in the subgroup of HCV (HR: 1.0, 95% CI: 0.9-1.0, P =0.44), HBV (HR: 1.2, 95% CI: 1.0-1.6, P =0.06), Alcohol (HR: 1.0, 95% CI: 1.0-1.1, P =0.50), NAFLD (HR: 1.0, 95% CI: 0.9-1.0, P =0.20) and others (HR: 1.1, 95% CI: 1.0-1.2, P =0.19). Finally, the hazard ratio associated with diabetes in the entire data set was 1.4 ( P =0.23).
Based on these univariate analyses, a multivariable model was constructed, in which age, serum albumin, and HCV etiology were signifi cantly associated with HCC. In pursuing the dichotomous relationship between diabetes and HCC for HCV and non-HCV patients, we tested for interaction between HCV and diabetes on the risk of HCC. In a multivariable model that adjusted for age, sex, race, and albumin, a statistically signifi cant interaction was found between diabetes and HCV. Table 3 explores this relationship further. In patients with HCV infection, diabetes was not associated with development of HCC (HR=0.6) in multivariable analysis in patients with HCV. In contrast, among non-HCV patients, diabetes was associated with nearly twofold increase in the risk of HCC (HR=1.9), although it did not reach statistical signifi cance. 
Association between diabetes and HCC in the HALT-C cohort
In the HALT-C data set, there were 410 patients with HCV cirrhosis with suffi cient data to allow assessment of the eff ect of diabetes on the risk of HCC. Relevant characteristics of the study subjects are summarized in Table 4 . In defi nition, all patients had compensated cirrhosis and their CTP and MELD scores were lower compared with the Mayo patients. Eighty (20%) patients had diabetes at baseline. As expected, diabetic patients were older and had higher BMI, and HOMA2-IR2 than non-diabetic patients. Overall, the CTP and MELD scores were comparable between diabetes and non-diabetes subjects, whereas the mean serum albumin was higher and serum bilirubin was lower in diabetic patients. Aft er a median follow-up of 72 months, 21 diabetic patients (26%) and 63 non-diabetic patients (19%) died, while nine patients with diabetes (11%) and 45 patients without (14%) underwent LT. Diabetes did not aff ect either outcome. Th e hazard ratio for diabetes was 1.5 for death (95% CI: 0.9-2.3, P =0.15) and 1.2 for LT (95% CI=0.6-2.4, P =0.61). With regard to the HCC outcome, there were 46 (11%) patients who developed HCC during the follow-up, including 7 (8%) with diabetes and 39 (12%) without. As depicted in Figure 2 , there was no diff erence in the incidence of HCC between diabetic and non-diabetic patients. Table 5 shows univariate and multivariable analyses replicating the analysis shown in Table 2 . Diabetes was not associated with HCC in univariate and multivariable analyses. Moreover, the hazard ratios associated with diabetes, albumin, and age in the latter model were essentially identical to those derived in Mayo patients with HCV infection. When HOMA2-IR2 was considered instead of diabetes, there was no association with HCC ( Supplementary Table ; Supplementary  Figure S3 ).
DISCUSSION
Th e aim of the current study was to investigate the eff ect of diabetes on the risk of HCC in patients with cirrhosis from diff erent etiologies. We demonstrate that the association was etiology-specifi c. In patients with non-HCV cirrhosis, diabetes was associated with approximately twofold increase (univariate HR=2.1 and mul- Diabetes has been associated with several human cancers ( 20 ) . Biologically plausible postulates for carcinogenic eff ects of diabetes on the liver have been proposed. Insulin resistance and subsequent production of reactive oxygen species triggering infl ammatory cascades may play a role in hepatocarcinogenesis ( 21 ) . Oxidative stress and release of proinfl ammatory cytokines such as TNF, IL-1, and IL-6 promote infl ammation of the liver. Proinfl ammatory cytokines are also known to stimulate growth of cancer cells and enhance their survival, as well as to promote angiogenesis and subversion from immunity ( 21 ) . In addition, insulin downregulates insulin-like growth factor binding protein1, which enhances bioavailability of insulin-like growth factor-1, promoting cellular proliferation and inhibiting apoptosis in the liver ( 22 ) . Finally, free fatty acids and infl ammatory cytokines in hyperinsulinemia are potent activators of c-Jun N-terminal kinase 1 ( 23 ) . c-Jun N-terminal kinase 1 mediates cell death and compensatory proliferation of hepatocytes and plays important roles in hepatocarcinogenesis (24) (25) (26) .
Despite these theories, epidemiological data linking diabetes to HCC have been confl icting, particularly for HCV-induced HCC. A multi-center study from Europe and Canada included 541 HCV patients with advanced fi brosis or cirrhosis (Ishak fi brosis score ≥4) who received interferon-based treatment with a median followup of 4 years ( 9 ). Th ere was no signifi cant association between diabetes and HCC in the entire study cohort, while in a subgroup of patients with Ishak score of 6 ( N =303), diabetes was associated with a threefold increase in HCC aft er adjusting for covariates. A Japanese cohort study with 4302 HCV patients reported that diabetes was associated with 1.7-fold increase in HCC risk in patients with HCV who received interferon-based treatment ( 27 ) . Th is association, however, was most pronounced in patients who had achieved sustained virologic response, in whom the risk increased 2.5-fold. In contrast, in a large population-based cohort study from Taiwan ( n =54,979), no association was found between diabetes and HCC (HR=0.62, P =0.37) among patients with HCV, although the study did not address patients with cirrhosis separately. Finally, in a study from Japan based on 161 HCV patients (39% with cirrhosis) with 6.4 years of follow-up, there was no association between diabetes and HCC aft er adjusting for other risk factors including cirrhosis ( 28 ) .
We believe that the results of this study may help understand these confl icting data by specifi cally studying patients with cirrhosis. As cirrhosis advances, the prevalence and severity of insulin resistance and diabetes increase ( 8, 9, 29 ) . In cirrhosis, impaired insulin secretion by the pancreas and insulin resistance and impaired insulin clearance in the liver have been described (30) (31) (32) (33) . Conversely, diabetes may accelerate progression of chronic liver disease ( 29, 34 ) . Insulin resistance creates a proinfl ammatory milieu, which promotes hepatocyte injury, infl ammation, and progression of liver disease ( 35 ) . Insulin also stimulates proliferation and collagen production of hepatic stellate cells ( 36 ) . Moreover, insulin and/or high glucose concentrations upregulates connective tissue factor, further contributing to liver fi brosis ( 37, 38 ) . Finally and importantly, cirrhosis remains by far the strongest risk factor for HCC and severity of fi brosis and hepatic decompensation parallel the risk of HCC ( 39, 40 ) . Th us, this complex relation among diabetes, cirrhosis, and HCC has likely created varying degrees of confounding in diff erent directions in prior studies.
Our study has several limitations. First, the retrospective nature of the study prevents systematic defi nition of variables based on objective biomarkers. For example, cirrhosis and advanced fi brosis may be best defi ned by liver histology or, more recently, by liver stiff ness measurement. Similarly, we may have under-diagnosed diabetes-however, we minimized misclassifi cation by incorporating use of anti-diabetic medications and plasma levels of fasting glucose and hemoglobin A1C in the defi nition of diabetes, in addition to the patient's report of diabetes. Second, as a single-center study, our patients were derived from a large referral practice at Mayo Clinic and the results might not be generalizable to cirrhotic patients at large. We demonstrate that our results are replicated almost exactly in the HALT-C data, a prospective, multi-center study. Th ird, while we started with a large number of patients with cirrhosis followed for a reasonable length of time, there were only a modest number of patients who developed HCC, especially when they were divided into several categories of liver disease, which limited the statistical power for multivariable analyses and led to relatively wide CIs. For example, for non-HCV patients in Table 3 , the hazard ratio for diabetes did not change materially between the univariate and multivariable analyses, whereas the P value for the latter was outside statistical signifi cance. For the HCV subgroup, lack of association between diabetes and HCC may constitute a type two error-although we believe that it is not very likely, because the point estimates are considerably <1 and consistent with each other (0.6 and 0.7) between the Mayo and the HALT-C data. Finally, the HALT-C study was conducted before modern non-invasive diagnostic criteria of HCC were established. Although there may be some cases that may not have met the current AASLD criteria, a sensitivity analysis performed while excluding patients with 'presumed' HCC ( n =12) yielded a similar result (HR: 1.0, 95% CI: 0.4-2.3, P =0.92).
In summary, in this study of patients with cirrhosis, diabetes was not associated with increased risk of HCC in patients with HCV, whereas in non-HCV patients, the hazard of HCC was two times higher in patients with diabetes compared with those without. Th ese results may be interpreted to indicate that in HCV patients who already have a very high risk of HCC, diabetes may not increase the risk any further. Th ese data highlight the need for care with which data linking diabetes to HCC are to be interpreted in patients with and without cirrhosis from diverse etiologies. Th ey also support further studies, particularly among non-HCV patients, to understand the impact of diabetes on HCC with higher specifi city according to the underlying etiology. In light of the emerging trends of increasing number of patients with NAFLD developing HCC, there is an urgent need to strategize stratifying their risk according to the metabolic profi le.
